宜明昂科-B(01541)：IMM0306治疗视神经嵴髓炎谱系疾病的IB期临床试验完成首例患者给药Jinli Group (00533) was privatized by Chairman Zeng Zhiming at a premium of about 24.85% and resumed trading IMMUNEONCO-B (01541) on December 18: IMM0306 completed the IB phase IB clinical trial to treat optic nerve spinal cord disease completed the first patient administration
[Important matters]
Alibaba-W (09988): Intended to sell Yintai
IMMUNEONCO-B (01541): IMM0306 completed the first patient administration in the IB phase clinical trial to treat optic nerve creatitis spectrum disease
Jinli Group (00533) was privatized by Chairman Zeng Zhiming at a premium of about 24.85% and resumed trading on December 18
Xintai Medical (02291): ScienCrown Transcatheter Implantable Aortic Valve System obtains medical device registration certificate
Hanson Pharmaceuticals (03692): HS-20110 for injection received a drug clinical trial approval notice issued by the State Drug Administration
Beijing Finance International (01468) plans to establish a joint venture to focus on operating and managing graphics processing unit server clusters in Thailand
China Xuyang Group (01907): Shenzhen Venture Capital plans to inject an additional 0.8 billion yuan into Cangzhou Xuyang Chemical
[Financial Report Data]
China Hongqiao (01378) Fayingxi expects annual net profit to increase by about 95% year-on-year
China Coal Energy (01898) commercial coal sales fell 1.9% year-on-year in the first 11 months of 0.256 billion tons
[Buy/Increase or Decrease Holds]
KUAISHOU-W (01024) spent HK$19.4791 million to buy back 0.43 million shares on December 17
AIA (01299) spent HK$0.455 billion to buy back 8.272 million shares on December 17
Tencent Holdings (00700) spent HK$0.703 billion to buy back 1.74 million shares on December 17
For more details, please refer to Zhitong Financial Network ()
